Compare FOSL & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOSL | LXEO |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.5M | 348.7M |
| IPO Year | 1994 | 2023 |
| Metric | FOSL | LXEO |
|---|---|---|
| Price | $5.87 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 650.1K | 645.2K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.26 | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,004,406,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $3.99 |
| 52 Week High | $6.25 | $10.99 |
| Indicator | FOSL | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 33.74 |
| Support Level | $3.83 | $4.01 |
| Resistance Level | $6.05 | $5.38 |
| Average True Range (ATR) | 0.30 | 0.23 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 97.39 | 5.10 |
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.